Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/202206
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Deoxynucleoside Therapy for Thymidine Kinase 2–Deficient Myopathy |
Autor: | Domínguez‐González, Cristina; Madruga, Marcos CSIC; Mavillard, Fabiola CSIC ORCID; Garone, Caterina; Aguirre-Rodríguez, Francisco Javier; Donati, Maria Alice; Kleinsteuber, Karin; Martí, Itxaso; Martín-Hernández, Elena; Morealejo‐Aycinena, Juan P.; Munell, Francina; Nascimento, Andrés; Kalko, Susana Graciela; Sardina, M. Dolores; Álvarez del Vayo Benito, Concepción CSIC; Serrano, Olga; Long, Yuelin; Tu, Yuqi; Levin, Bruce; Thompson, John L. P.; Engelstad, Kristen; Uddin, Jasim; Torres‐Torronteras, Javier; Jiménez‐Mallebrera, Cecilia; Martí, Ramón; Paradas, Carmen CSIC ORCID; Hirano, Michio | Fecha de publicación: | ago-2019 | Editor: | Wiley-Blackwell | Citación: | Annals of Neurology 86(2): 293-303 (2019) | Resumen: | [Objective] Thymidine kinase 2, encoded by the nuclear gene TK2, is required for mitochondrial DNA maintenance. Autosomal recessive TK2 mutations cause depletion and multiple deletions of mtDNA that manifest predominantly as a myopathy usually beginning in childhood and progressing relentlessly. We investigated the safety and efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies. [Methods] We administered deoxynucleoside monophosphates and deoxynucleoside to 16 TK2‐deficient patients under a compassionate use program. [Results] In 5 patients with early onset and severe disease, survival and motor functions were better than historically untreated patients. In 11 childhood and adult onset patients, clinical measures stabilized or improved. Three of 8 patients who were nonambulatory at baseline gained the ability to walk on therapy; 4 of 5 patients who required enteric nutrition were able to discontinue feeding tube use; and 1 of 9 patients who required mechanical ventilation became able to breathe independently. In motor functional scales, improvements were observed in the 6‐minute walk test performance in 7 of 8 subjects, Egen Klassifikation in 2 of 3, and North Star Ambulatory Assessment in all 5 tested. Baseline elevated serum growth differentiation factor 15 levels decreased with treatment in all 7 patients tested. A side effect observed in 8 of the 16 patients was dose‐dependent diarrhea, which did not require withdrawal of treatment. Among 12 other TK2 patients treated with deoxynucleoside, 2 adults developed elevated liver enzymes that normalized following discontinuation of therapy. [Interpretation] This open‐label study indicates favorable side effect profiles and clinical efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies for TK2 deficiency. ANN NEUROL 2019;86:293–303 |
Versión del editor: | https://doi.org/10.1002/ana.25506 | URI: | http://hdl.handle.net/10261/202206 | DOI: | 10.1002/ana.25506 | ISSN: | 0364-5134 | E-ISSN: | 1531-8249 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
43
checked on 10-abr-2024
SCOPUSTM
Citations
67
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
55
checked on 25-feb-2024
Page view(s)
173
checked on 16-abr-2024
Download(s)
19
checked on 16-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.